RecoveryIn Clinical Trials

Nexagon (Gap Junction Peptide)

Topical

Overview

Nexagon is a synthetic peptide designed to transiently modulate gap junction intercellular communication by mimicking a segment of the connexin protein family. The mechanism involves temporary inhibition of connexin43-mediated channels during the early inflammatory phase of wound healing, which may reduce inflammatory cell infiltration and subsequent scar formation.

Mechanism of Action

This approach aims to shift the healing process toward regeneration rather than fibrosis..

Research Summary & Key Findings

Early clinical studies in venous leg ulcers demonstrated improved healing rates and reduced scar tissue formation. A phase II trial showed statistically significant reduction in scar size when applied topically to acute wounds, though larger confirmatory trials have not been widely published.

Clinical Status

In Clinical Trials

Nexagon (Gap Junction Peptide) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Topical

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers Nexagon (Gap Junction Peptide) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Nexagon (Gap Junction Peptide).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.